Barrett Esophagus Clinical Trials

Find Barrett Esophagus Clinical Trials Near You

First-in-Human Pilot Study for the Evaluation of Digma Medical's Endoscopic Gastrointestinal Ablation Device (EGAD) in the Esophagus

Status: Recruiting
Intervention Type: Device
Study Type: Interventional
Study Phase: Not Applicable
SUMMARY

Prospective, open-label, single-arm, early feasibility study (EFS) in 2 Patient cohorts: Cohort A - Dose finding / Dose response study in patients with various etiologies undergoing Esophagectomy and Cohort B - Patients with Barrett's Esophagus (BE) with Low-Grade Dysplasia (LDG) or High-Grade Dysplasia (HGD) without a visible (excisable) lesion. This is a pilot study which plan to enroll up to 5 eligible patients in the First Cohort (A) and up to 15 patients in the Second Cohort (B) of the study.

Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Maximum Age: 70
Healthy Volunteers: f
View:

⁃ Cohort A:

• Male or Female ≥18 years of age at the time of consent.

• Scheduled to undergo esophagectomy for malignant or benign indications .

• Contain enough healthy (or with BE) tissue to be ablated (≥1cm) by for EGAD treatment.

• Capable of providing written informed consent.

⁃ Cohort B:

• Male or Female ≥18 and ≤ 70 years of age at the time of consent.

• Documented diagnosis of Barrett's Esophagus (BE) with LGD or HGD, confirmed by biopsy specimen analysis.

• No visible lesion in the esophagus (suitable for endoscopic resection).

• Scheduled to undergo Endoscopic eradication therapy (EET) procedure of Barrett's Esophagus (BE) with dysplasia.

• BE affected tissue length ≥1 cm and ≤ 5cm (as measured endoscopically).

• Capable of providing written informed consent.

• Willingness and ability to comply with follow-up requirements, including endoscopies and biopsies.

• Ability to tolerate and take oral proton pump inhibitor (PPI) medication.

Contact Information
Primary
Shlomit Chappel-Ram, BSc,PhD
shlomitc@digmamedical.com
+972544644518
Time Frame
Start Date: 2026-05-25
Estimated Completion Date: 2027-12-31
Participants
Target number of participants: 20
Treatments
Experimental: Endoscopic Gastrointestinal Ablation Device (EGAD)
Application of different doses of laser energy in the ablation of esophageal mucosa using the Digma System and the EGAD procedure (Cohort A) followed by application of the optimal dose for treatment of patients with BE with LGD or HDG without a visible lesion (Cohort B).
Related Therapeutic Areas
Sponsors
Leads: Digma Medical Ltd.

This content was sourced from clinicaltrials.gov